诺和诺德阿尔茨海默症试验失败

Core Viewpoint - Novo Nordisk's semaglutide failed to delay the progression of Alzheimer's disease, leading to a decline in its stock price, while Eli Lilly and Biogen saw their stock prices rise due to improved relative expectations [1] Company Summary - Novo Nordisk's stock price is under pressure following the announcement regarding semaglutide's ineffectiveness in Alzheimer's treatment [1] - Eli Lilly's stock price increased as market expectations improved in light of the news [1] - Biogen also experienced a rise in stock price, benefiting from the relative positive outlook compared to Novo Nordisk [1]